APLMW (Apollomics) Stock Based Compensation: $-0.98 Mil (TTM As of Dec. 2025)


APLMW Apollomics Inc APLMW
31 GF Score
Price $0.02
! 4 Warning Signs
View Full Analysis

What is Apollomics Stock Based Compensation?

Apollomics APLMW +33.09% 31 Stock Based Compensation is $-0.98 Mil as of Dec. 2025. GuruFocus rates APLMW with a GF Score™ of 31/100. The stock has 4 warning signs investors should review.

Apollomics's Stock Based Compensation for the six months ended in Dec. 2025 was $-4.25 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.98 Mil.

Apollomics Stock Based Compensation Related Terms

Apollomics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Apollomics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apollomics Stock Based Compensation Chart

Apollomics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 8.12 3.58 12.69 10.93 -0.98

Apollomics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 7.40 8.22 2.70 3.27 -4.25
APLMW
31GF Score
Apollomics Inc APLMW
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apollomics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.98 Mil.

What does a Stock Based Compensation of $-0.98 Mil mean?
Apollomics (APLMW) has a Stock Based Compensation of $-0.98 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Apollomics and its competitors.
Is Apollomics' Stock Based Compensation too high?
Apollomics' current Stock Based Compensation is $-0.98 Mil. Overall, Apollomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Apollomics' Stock Based Compensation compare to HYPD and MGX?
Apollomics' Stock Based Compensation of $-0.98 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Apollomics and its competitors. Apollomics's current Stock Based Compensation is $-0.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apollomics stock overvalued right now?
Apollomics (APLMW) has a current Stock Based Compensation of $-0.98 Mil. The current Stock Based Compensation is $-0.98 Mil. Apollomics' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Apollomics (APLMW), the current Stock Based Compensation is $-0.98 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apollomics Business Description

Other Exchanges APLM:USA
Address 989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
31GF Score

Get the complete analysis for APLMW

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price